Shots:

• The P-III VANISH-306 study evaluates ibrexafungerp vs PBO in women aged ≥12yrs. with VVC. The results were published in the International Journal of Obstetrics and Gynaecology (BJOG)
• The 1EPs & 2EPs of the study showed that the patients treated with ibrexafungerp had higher rates of clinical cure (63.3% vs. 44.0%). The results also showed higher rates in mycological eradication (58.5% vs 29.8%) @10Day, and clinical improvement (72.3% vs. 54.8%). The therapy was generally well-tolerated
• Additionally, the therapy showed a sustained symptom resolution @25 days (73.9% vs 52.4%) & complete symptom resolution in patients with C. Albicans at baseline (77.0% vs 52.6%), respectively

Click here to­ read full press release/ article | Ref: Globe Newswire | Image: Scynexis